About 30 results found for searched term "GSK-3" (0.005 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1719 | GSK461364 | PLK |
| GSK461364A | ||
| GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. | ||
| M1758 | Foretinib | c-Met |
| XL880, GSK1363089 | ||
| Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. | ||
| M1789 | GSK690693 | Akt |
| GSK-690693 | ||
| GSK690693 is a potent Akt inhibitor (Akt1 IC50 = 2 nM, Akt2 IC50 = 13 nM, Akt3 IC50 = 9 nM) which also inhibited the phosphorylation of the downstream target GSK3b in cells. | ||
| M1855 | Dabrafenib Mesylate | Raf |
| GSK-2118436B | ||
| Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. | ||
| M1932 | GSK1838705A | ALK |
| GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively. | ||
| M1988 | Dabrafenib | Raf |
| GSK2118436 | ||
| Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. | ||
| M2033 | GSK 3787 | PPAR |
| GSK3787 | ||
| GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). | ||
| M2050 | GSK2636771 | PI3K |
| GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. | ||
| M2115 | GSK2334470 | PDK1 |
| GSK2334470 is a highly specific and potent inhibitor of PDK1 with IC50 of 10 nM. | ||
| M2171 | GSK923295 | Kinesin |
| GSK923295 is an allosteric inhibitor of CENP-E with Ki value of 3.2 nM. | ||
| M2405 | AR-A014418 | GSK-3 |
| GSK-3β Inhibitor VIII | ||
| AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested. | ||
| M2736 | GSK343 | EZH2 |
| GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. | ||
| M3054 | TDZD-8 | GSK-3 |
| GSK-3β Inhibitor I; NP 01139 | ||
| TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | ||
| M3321 | GSK1292263 | GPR/FFAR |
| GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. | ||
| M3484 | Dolutegravir | Integrase |
| GSK1349572 | ||
| Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. | ||
| M3715 | GSK2838232A | HIV Protease |
| GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. | ||
| M3751 | Losmapimod | p38 MAPK |
| GW-856553X; GSK-AHAB; SB856553 | ||
| Losmapimod (GW856553) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. | ||
| M4804 | GSK-503 | Histone Methyltransferase |
| GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. | ||
| M4824 | Dolutegravir sodium | Integrase |
| GSK-1349572A, DTG | ||
| Dolutegravir sodium is a potent, second generation HIV integrase inhibitor (IC₅₀ = 2.7 nM) that displays potent antiviral activity. | ||
| M4954 | EPZ015666 | PRMTs |
| GSK3235025 | ||
| EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs. | ||
| M5187 | GSK137647A | GPR/FFAR |
| GSK 137647 | ||
| GSK137647A is a selective FFAR4 (GRP120) agonist for human, Mouse and Rat FFA4 with pEC50 values of 6.3, 6.2 and 6.1, respectively. GSK137647A induces insulin secretion and inhibits epithelial ion transport. | ||
| M5210 | GSK1325756 (Danirixin) | CXCR |
| Danirixin | ||
| GSK1325756 (Danirixin) is a non-peptide, high affinity, selective and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. | ||
| M5232 | GSK583 | RIPK |
| GSK583 is a highly potent and selective inhibitor of RIP2 kinase with an IC50 of 5 nM. | ||
| M5269 | GSK180736A | ROCK |
| GSK180736 | ||
| GSK180736A, developed as a Rho-associated, coiled-coil-containing protein kinase inhibitor, binds to GRK2(G protein-coupled receptor kinase 2) with logIC50 pf -6.6 (logIC50 -4.0 for GRK5 and >-3 for GRK1); ≥400-fold selective for GRK2 over both GRK1 and GRK5. | ||
| M5271 | GSK6853 | Epigenetic Reader Domain |
| GSK6853 is a selective benzimidazolone BRPF1 inhibitor with pIC50 of 8.1(TR-FRET) showing greater than 1600-fold selectivity over all other bromodomains tested. | ||
| M5308 | Afuresertib | Akt |
| GSK2110183; LAE002 | ||
| Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. | ||
| M5325 | GSK 650394 | SGK |
| GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively. | ||
| M6161 | GSK369796 Dihydrochloride | Potassium Channel |
| GSK369796 shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. | ||
| M6768 | GSK2033 | Liver X Receptor |
| GSK 2033 | ||
| GSK2033 is a potent LXR antagonist. | ||
| M6770 | GSK 2830371 | Phosphatase |
| GSK 2830371 is a potent and selective allosteric inhibitor of Wip1 phosphatase. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
